pharma semaglutide / Glycine – WP Labs Key reasons behind surge in

Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice

5.59 per cent of the obese population in 2024 uses GLP-1R agonists in the 7MM, and this is expected to grow to 12.11 per cent of the obese population in 2033. The rising patient base and rise in prescriptions have created a cascade across the ecosystem-from formulation innovation to delivery systems

In the 68-week trial, semaglutide showed a mean weight change of 15.8% compared to liraglutide's 6.4%

While GLP-1 receptor agonists like semaglutide and tirzepatide are now widely used for weight loss, research to understand their impact on eye health has largely been limited to diabetic patients

Gastroparesis is a condition where the stomach stops moving as it normally does